Frontlight ResearchEarly access
Hypertrophic cardiomyopathy trials in Netherlands
4 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Imbria Pharmaceuticals Inc.
See details and how to join2024-515125-28-00 - Phase 2Taking peopleA Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Where
- Amsterdam-Zuidoost, Leiden, Nijmegen, Rotterdam
- Age
- 18 years and over
- People
- 165 worldwide
- Run by
- Imbria Pharmaceuticals, Inc.
See details and how to joinNCT07023614 - Phase 2/3Taking peopleOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
- Where
- Amsterdam, Maastricht, Rotterdam
- Age
- 18 years to 85 years
- People
- 900 worldwide
- Run by
- Cytokinetics
See details and how to joinNCT04848506 · EU 2023-508963-58-00 - Phase 2Not yet taking people in NetherlandsLEAF‑HCM: What can we learn from the early use of aficamten in people who have no symptoms but do have a thickened heart muscle with blood flow obstruction?
- Where
- Rotterdam
- Age
- 18 years and over
- People
- 50
- Run by
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2025-523090-42-00